文献速递肾移植肾小球疾病血液净化与透析

高度个体化补体阻断显著改善肾移植后非典型溶血性尿毒症综合征的预后与流行病学

Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
PubMed 文献 · J Am Soc Nephrol · 2019-10-01

法国一项多中心回顾性研究纳入126例肾移植(116例患者),其中52例使用依库珠单抗预防,结果显示预防性依库珠单抗与降低aHUS复发风险及延长移植物存活独立相关。另一项基于人群的队列研究(397例aHUS患者)显示2012至2016年移植比例从46.2%升至72.3%,与依库珠单抗使用增加密切相关。

要点

  • 高风险aHUS患者肾移植后预防性使用依库珠单抗可显著降低复发风险。
  • 预防性依库珠单抗与更长的移植物存活独立相关。
  • 2012至2016年法国aHUS透析患者中移植比例从46.2%升至72.3%。

核心结论

  • 基于移植前风险分层的依库珠单抗预防与aHUS肾移植后复发风险降低和移植物存活延长相关。

研究设计与样本

  • 回顾性多中心研究纳入法国全国登记中2007年1月1日后接受肾移植并完成补体分析的成人aHUS患者,共126例移植(116例患者)。
  • 基于人群的队列研究纳入2007至2016年法国所有成人aHUS患者(n=397)。

主要发现

  • 126例移植中58.7%为高复发风险,34.1%为中风险;52例移植使用了依库珠单抗预防,其中39例为高风险。
  • 移植后aHUS复发43例(34.1%),其中4例接受了依库珠单抗预防,39例未接受。
  • 预防性依库珠单抗使用与显著降低的复发风险和显著更长的移植物存活独立相关。
  • 基于人群队列中,2012至2016年ESKD合并aHUS患者中移植受者比例从46.2%升至72.3%,与移植受者中依库珠单抗使用增加密切相关。

临床怎么用

  • 对aHUS肾移植候选者应进行移植前风险分层,高风险患者可考虑预防性依库珠单抗。
  • 预防性依库珠单抗可能改善移植物存活,但需权衡个体化获益与风险。

局限性

  • 本研究为观察性研究,结果支持但不足以证明因果,需严谨的随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence rates after kidney transplant, with devastating outcomes. In late 2011, experts in France recommended the use of highly individualized complement blockade-based prophylaxis with eculizumab to prevent post-transplant atypical HUS recurrence throughout the country. METHODS: To evaluate this strategy's effect on kidney transplant prognosis, we conducted a retrospective multicenter study from a large French nationwide registry, enrolling all adult patients with atypical HUS who had undergone complement analysis and a kidney transplant since January 1, 2007. To assess how atypical HUS epidemiology in France in the eculizumab era evolved, we undertook a population-based cohort study that included all adult patients with atypical HUS (n=397) between 2007 and 2016. RESULTS: The first study included 126 kidney transplants performed in 116 patients, 58.7% and 34.1% of which were considered to be at a high and moderate risk of atypical HUS recurrence, respectively. Eculizumab prophylaxis was used in 52 kidney transplants, including 39 at high risk of recurrence. Atypical HUS recurred after 43 (34.1%) of the transplants; in four cases, patients had received eculizumab prophylaxis and in 39 cases they did not. Use of prophylactic eculizumab was independently associated with a significantly reduced risk of recurrence and with significantly longer graft survival. In the second, population-based cohort study, the proportion of transplant recipients among patients with ESKD and atypical HUS sharply increased between 2012 and 2016, from 46.2% to 72.3%, and showed a close correlation with increasing eculizumab use among the transplant recipients. CONCLUSIONS: Results from this observational study are consistent with benefit from eculizumab prophylaxis based on pretransplant risk stratification and support the need for a rigorous randomized trial.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zuber J, Frimat M, Caillard S, et al. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2019. PMID: 31575699. doi:10.1681/ASN.2019040331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。